Archived 24: National Advisory Committee on Immunization (NACI) statement: Recommendation on the use of the Pfizer-BioNTech COVID-19 vaccine (10 mcg) in children 5 to 11 years of age [2021-11-19]

Notice to reader

This is an archived version. Please refer to current COVID-19 vaccine pages:

Publication date: November 19, 2021

On this page


The National Advisory Committee on Immunization (NACI) is an External Advisory Body that provides the Public Health Agency of Canada (PHAC) with independent, ongoing and timely medical, scientific, and public health advice in response to questions from PHAC relating to immunization.

In addition to burden of disease and vaccine characteristics, PHAC has expanded the mandate of NACI to include the systematic consideration of programmatic factors in developing evidence-based recommendations to facilitate timely decision-making for publicly funded vaccine programs at provincial and territorial levels.

The additional factors to be systematically considered by NACI include: economics, ethics, equity, feasibility, and acceptability. Not all NACI Statements will require in-depth analyses of all programmatic factors. While systematic consideration of programmatic factors will be conducted using evidence-informed tools to identify distinct issues that could impact decision-making for recommendation development, only distinct issues identified as being specific to the vaccine or vaccine-preventable disease will be included.

This statement contains NACI's independent advice and recommendations, which are based upon the best current available scientific knowledge. This document is being disseminated for information purposes. People administering the vaccine should also be aware of the contents of the relevant product monograph. Recommendations for use and other information set out herein may differ from that set out in the product monographs of the Canadian manufacturers of the vaccines. Manufacturer(s) have sought approval of the vaccines and provided evidence as to its safety and efficacy only when it is used in accordance with the product monographs. NACI members and liaison members conduct themselves within the context of PHAC's Policy on Conflict of Interest, including yearly declaration of potential conflict of interest.


The Pfizer-BioNTech (Comirnaty) mRNA COVID-19 vaccine is the first COVID-19 vaccine authorized in Canada for use in pediatric populations under the age of 12 years. Pfizer-BioNTech [10 microgram (mcg) dose] was approved for children 5-11 years of age on November 19, 2021. The Pfizer-BioNTech (Comirnaty) COVID-19 vaccine has been previously authorized by Health Canada as follows:

On May 18, 2021, following Health Canada authorization of the Pfizer-BioNTech vaccine (30 mcg dose) for individuals 12 to 15 years of age under the Interim Order, NACI recommended the use of the vaccine in adolescents (Strong NACI Recommendation) based on a review of available evidence including additional clinical trial results in the adolescent population. On August 27, 2021, Health Canada expanded the Interim Order authorization for the Moderna (SpikeVax) COVID-19 vaccine to also include adolescents 12 to 17 years of age. That same day, NACI issued updated guidance on the use of mRNA COVID-19 vaccines in adolescents, incorporating additional evidence including clinical data on the efficacy, safety, and immunogenicity of the Moderna COVID-19 vaccine in adolescents as well as post-market safety and effectiveness reports on both mRNA COVID-19 vaccines. Subsequently, Moderna received full authorization on September 16, 2021 for individuals 12 years of age and over under the name Spikevax.

For further information on the use of the Pfizer-BioNTech vaccine in individuals 12 years of age and older, please refer to NACI's recommendations on the use of COVID-19 vaccines and NACI's recommendation on the use of mRNA COVID-19 vaccines in adolescents 12 to 17 years of age.

NACI's recommendations are aligned with the following goals of the Canadian COVID-19 Immunization Program, updated in October, 2021:

  1. To enable as many Canadians as possible to be immunized as quickly as possible against COVID-19, while ensuring that high risk populations be prioritized
  2. Minimize serious illness and overall deaths while preserving health system capacity
  3. Reduce transmission to protect high risk populations.


On October 26, 2021 and November 2, 2021, NACI reviewed the available evidence on the use of the Pfizer-BioNTech COVID-19 vaccine (10 mcg dose) in children 5-11 years of age (including manufacturer's clinical data in the regulatory submission to Health Canada, modeling projections on the impact of a pediatric vaccine program, and post-market safety data for the 30 mcg dose in older age groups). Ethical considerations related to COVID-19 vaccination in pediatric populations were discussed with the Public Health Ethics Consultative Group (PHECG) on May 3, 2021, July 6, 2021 and September 21, 2021. The Canadian Immunization Committee (CIC) provided feedback on key policy questions to ensure alignment with program needs on October 21, 2021. NACI approved their recommendations on the use of mRNA COVID-19 vaccines in children 5-11 years of age on November 11, 2021.

Details of NACI's evidence-informed recommendation development process can be found elsewhereFootnote 1Footnote 2.

Summary of evidence

COVID-19 burden of disease in children

Children 5-11 years of age generally present with mild or asymptomatic SARS-CoV-2 infection. Among the 12 jurisdictions currently reporting detailed age data to PHAC, severe outcomes from COVID-19 such as hospitalization and death are very infrequent in children, occurring in <0.3% and <0.002% of confirmed SARS-CoV-2 infections in children aged 5-11 years. As of November 09, 2021, children aged 5-11 years represent 7.5% of confirmed SARS-CoV-2 infections, 0.3% of COVID-19 associated hospitalizations, 0.3% of COVID-19 associated ICU admissions, and 0.007% of COVID-19 deaths in CanadaFootnote 3. Persons 12 years of age and older have been eligible to receive COVID-19 vaccines since at least May 2021, depending on age, and recently children 5-11 years of age have represented the population with the highest incidence of confirmed SARS-CoV-2 infection, although hospitalization rates in this age group have remained low during the fourth wave of the pandemic. While the exact prevalence of SARS-CoV-2 seropositivity among children aged 5-11 years is unknown, seroprevalence estimates in children from studies based in Quebec and British Columbia suggest case-level data is likely an underestimate of infection in this age groupFootnote 4.

Children and adolescents are at risk of multisystem inflammatory syndrome in children (MIS-C) following infection with SARS-CoV-2Footnote 5. In these age groups, MIS-C is a serious, though uncommon, condition. MIS-C is more frequently reported in males and members of racialized groups or populations, with infrequent comorbidities reported aside from obesity.Footnote 6Footnote 7 A large international cohort study on children with COVID-19 estimated MIS-C to affect between 0.5%-3.1% of all diagnosed pediatric COVID-19 patients and between 0.9%-7.6% of hospitalized pediatric COVID-19 patientsFootnote 8. As of October 16, 2021, 272 cases of MIS-C in individuals 0-19 years of age have been reported in CanadaFootnote 9. Of these nationally reported cases, over half (59%) were in males, and 40% of cases occurred in children aged 5-11 years, with a median age of 6 years (range: 1 week to 18 years), and 40% of cases occurred in children aged 5 to 11 years. The majority of MIS-C cases in Canada have fully recovered with medical intervention, with no MIS-C associated deathsFootnote 9.

Myocarditis can also occur as a complication of SARS-CoV-2 infection, including [very rarely] in childrenFootnote 10.

While evidence is limited in pediatric populations, children may also be at risk of a post-COVID-19 condition (i.e., long COVID or post acute COVID-19 syndromeFootnote 11). However, current evidence suggests the risk is lower in children compared to older age groupsFootnote 12Footnote 13.

Children are also at risk of collateral harms of the COVID-19 pandemic. Prolonged schooling disruptions, social isolation, and reduced access to academic and extra-curricular resources have had profound impact on the mental and physical well-being of children and their families. These harms can disproportionately affect some Canadian children and families as compared to others, and the impacts of these harms may further exacerbate social inequities among racialized and Indigenous communities, refugees and other newcomers to Canada, persons living in low-income settings, as well as children with disabilitiesFootnote 14Footnote 15Footnote 16Footnotee 17Footnote 18Footnote 19.

Risk factors most frequently associated with severe disease in school-aged children

There is limited evidence on clinical risk factors for severe COVID-19 disease in children aged 5-11 yearsFootnote 20. While not specific to pediatric populations, a rapid review of age-independent risk factors for severe COVID-19 conducted by the Alberta Research Centre for Health Evidence (ARCHE)Footnote 21 identified strong evidence (moderate or high certainty) for a ≥2-fold increase in mortality from COVID-19, for individuals with Down Syndrome, end-stage kidney disease, epilepsy, neurological disorders including motor neuron disease, multiple sclerosis, myasthenia gravis, and Huntington's disease, as well as type 1 and 2 diabetes. Obesity (BMI >40) was also identified as a risk factor for a ≥2-fold increase in mortality from COVID-19 (low certainty of evidence). Specifically for individuals 21 years of age and younger, having multiple (≥2) chronic comorbidities was identified as a risk factor for severe COVID-19 (moderate certainty of evidence)Footnote 21. Several recent cohort studies in children and adolescents (≤18 years of age) hospitalized for COVID-19 identified the presence of multiple comorbiditiesFootnote 22Footnote 23, obesityFootnote 22Footnote 23Footnote 24, neurological disordersFootnote 22Footnote 24, feeding tube dependenceFootnote 23, and congregate living settingsFootnote 23 as independent risk factors for severe COVID-19. Although the relative risk for severe outcomes of COVID-19 may be substantial for children with the comorbidities specified above, the magnitude of the absolute excess risk remains small.

Implications of the SARS-CoV-2 Delta variant on COVID-19 in children

Due to its increased transmissibility compared to other variants of concern, the SARS-CoV-2 Delta variant may pose a higher risk of infection for children when in congregate settings, including in-person schooling, compared to other variants. The Delta variant has been the predominant circulating SARS-CoV-2 strain in Canada since June 2021. A recent rapid review conducted by the Public Health Agency of Canada estimates the Delta variant has increased transmissibility over the Alpha variant by 43-115%Footnote 25. However, data from CanadaFootnote 26 and the United States (US)Footnote 27 suggest that COVID-19 disease severity in children since June 2021 remains consistent with previous waves of the pandemic.

Clinical trial data on the Pfizer-BioNTech mRNA COVID-19 vaccine in children 5-11 years of age

Trial design: The Pfizer-BioNTech COVID-19 vaccine was evaluated in an ongoing, randomized, observer-blind, placebo-controlled Phase 1/2/3 clinical trial in healthy children from 6 months to 11 years of age (C4591007)Footnote 28. In the Phase 1 dose finding trial, due to the frequency and severity of reactogenicity observed with a 30 mcg dose in the first 4 children 5-11 years of age that received two doses, 30 mcg each, the internal review committee (IRC) recommended that the 30 mcg dose be discontinued and the remaining participants who received 30 mcg as dose 1 received 10 mcg for dose 2 instead (n=12). Based on the reactogenicity and immunogenicity observed in the initial cohort of children 5-11 years of age in the Phase 1 trial, a dose of 10 mcg was selected for the Phase 2/3 trial for this age group. At time of regulatory submission, two cohorts totalling 4,647 participants (initial enrolment cohort: n=2,268; a further safety cohort: n=2,379) 5-11 years of age were randomized 2:1 to receive either two doses of the vaccine (10 mcg mRNA; n=3,109) or placebo (n=1,538), 21 days apart. Follow-up is planned for up to approximately 2 years following the second dose.

Study population: All pediatric study participants for the Phase 2/3 trial were recruited from the US, Finland, Poland and Spain. Children with a history of prior SARS-CoV-2 infection or clinical symptoms/signs of COVID-19, children with known HIV, hepatitis B or hepatitis C, or stable pre-existing disease (defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrollment) were included. Children with an immunocompromising or immunodeficiency disorder, those with a history of MIS-C, or those receiving immunosuppressive therapy (including cytotoxic agents and systemic glucocorticoids) were excluded.

Cohort 1: 1,518 participants randomized to receive the Pfizer-BioNTech COVID-19 vaccine (10 mcg); 750 randomized to receive placebo, with a minimum duration of safety follow-up of 2-months post second dose (median duration of follow-up 3.3 months; data cut-off October 8, 2021). A preliminary descriptive efficacy analysis was also based on this cohort. A randomly selected subset of Cohort 1 was included in the immunogenicity analysis detailed below.

Cohort 2: 1,591 participants randomized to receive the Pfizer-BioNTech COVID-19 vaccine (10 mcg); 788 randomized to receive placebo, with a median duration of safety follow-up of 2.4 weeks post second dose (data cut-off October 8, 2021). Interim safety data from Cohort 2 were provided at the time of regulatory submission.

Immunogenicity comparator group: This was a randomly selected subset (n=300) of participants aged 16- 25 years from the earlier Phase 2/3 study C4591001 who received two doses of the Pfizer-BioNTech COVID-19 vaccine (30 mcg), 21 days apart.

Demographics: Demographic characteristics were similar in Cohort 1 and Cohort 2 study participants. Overall, 48.6% of participants were female, the median age at vaccination was 8.0 years (range: 5-11 years), 20% of participants had an underlying comorbidity, and the most commonly reported comorbidity was obesity (BMI ≥ 95th percentile; 11.4% of participants). 8.7% of participants in Cohort 1 and 10.3% of participants in Cohort 2 reported a positive baseline status for SARS-CoV-2 infection. No participants aged 5-11 years with known HIV were enrolled in the trial.

Safety: Overall, the Pfizer-BioNTech COVID-19 vaccine was well tolerated in children 5-11 years of age. The frequencies of reported solicited local and systemic events are provided in the Appendix. Local reactions were very common and mostly mild to moderate in severity. The median onset of solicited local reactions was 1-2 days after any dose and reactions resolved after a median of 1-2 days. Compared to Phase 3 participants ≥12 years of age in study C4591001 (who received a 30 mcg dose), children 5-11 years of age that received a 10 mcg dose had similar frequencies of pain at the injection site and higher frequencies of swelling and redness.

Systemic events were predominantly fatigue, headaches, muscle pain, chills, fever, and joint pain (in order of descending frequency) and occurred more frequently after the second dose. Fatigue after dose 1 occurred at similar rates in the vaccinated and placebo group, but was higher in the vaccinated group, compared to placebo, after dose 2. The median onset day for most solicited systemic events after either dose of vaccine was 1 to 4 days post-vaccination, with a median duration of 1 day. Most systemic events were mild or moderate in severity. In the vaccine group, the highest frequencies of systemic events graded as severe after dose 1 and dose 2 were for fatigue (0.3% and 0.7%); fever > 38.9°C after dose 1 and dose 2 was reported in 0.2% and 0.6% of participants. One vaccinated participant had a fever of 40.0°C that occurred 2 days after dose 2 and resolved within 1 day.

Compared to Phase 3 participants ≥ 12 years of age in study C4591001 (who received a 30 mcg dose), systemic reactogenicity in children 5-11 years of age receiving a 10 mcg dose was comparable and less frequent for some events (such as fever, chills, headache, and fatigue).

Serious adverse events and other adverse events of interest

In Cohort 1 participants 5-11 years of age (vaccine, n=1,518 and placebo n=750), vaccination-related lymphadenopathy (unsolicited adverse event [AE]) occurred in 0.7% of vaccine recipients. A 6-year-old female in the vaccine group, had an AE of Henoch-Schonlein purpura which was diagnosed 21 days after dose 1 and was considered non-serious. A 5-year-old female in the vaccine group with transient neutropenia reported at baseline, had an AE of severe neutropenia (worsening from baseline) which was diagnosed 3 days after dose 1 and was considered non-serious and related to the intervention. The patient was withdrawn from the study and dose 2 was not administered. No allergic events or anaphylactoid reactions were reported after either dose. No serious adverse events (SAE) related to the vaccine, no cases of MIS-C, myocarditis/pericarditis or deaths were reported. Given the trial was limited to n=3,109 participants randomized to receive the Pfizer-BioNTech vaccine, it is unlikely that any AE occurring at a frequency less often than 1 in 1,000 would be detected.

Expanded safety data

The findings for Cohort 2 participants (vaccine, n= 1,591 and placebo, n= 778 for placebo) were limited to a median follow-up duration of 2.4 weeks after dose 2 at time of data cut-off.

Preliminary safety data available on Cohort 2 participants suggested a similar profile to the initial safety datasetFootnote 29. No cases of myocarditis/pericarditis, MIS-C, anaphylaxis or anaphylactoid reactions or deaths were reported.

Concurrent administration with other vaccines

A small percentage (≤0.8%) of trial participants were administered a different non COVID-19 vaccine concurrently with the Pfizer-BioNTech vaccine or placebo. No analyses were performed to determine the impact of concurrent administration of other vaccines on safety or other outcomes.

Immunogenicity: The humoral immune response was evaluated based on SARS-CoV-2 50% neutralizing antibody titres (NT-50) assessed one month following the second dose. A 1.5-fold non-inferiority criterion was pre-established to compare immune responses in children 5-11 years of age to that in adolescents and young adults 16-25 years of age (point estimate of the geometric mean ratio [GMR] of titres ≥0.8 and lower bound of the 2-sided 95% confidence interval (CI) for the GMR of titres >0.67). The GMR of titres in children 5-11 years of age (n=264) relative to those in 16- 25 years of age (n=253) was 1.04 (95% CI: 0.93 to 1.18), meeting both criteria for non-inferiority. Immunogenicity data in children following dose 1 and prior to dose 2 were not assessed.

A smaller randomly selected subset of 38 participants aged 5-11 years were assessed for neutralization titres against both the Delta variant and wild-type strain using a non-validated plaque reduction neutralization assay. Of the 38 participants, 34 received the vaccine and 4 received placebo, and all were without evidence of prior SARS-CoV-2 infection. Neutralization of both the wild-type strain and the Delta variant were comparable by NT-50 assay in participants that received the vaccine, one month following dose 2 [GMT: 365.3 (95% CI: 279.0 to 478.4) for the wild-type strain, and 294.0 (95% CI: 214.6 to 405.3) for the Delta variant]. Participants that received the placebo had a GMT of 10 (95% CI: 10 to 10) for both the wild-type and the Delta variant.

Recent evidence suggesting that neutralizing antibodies may serve as a correlate of protection for vaccines against SARS-CoV-2 in humans is evolvingFootnote 30. However, since no correlate of protection has been established for COVID-19 at this time, it is unknown how reported immune responses are related to prevention of SARS-CoV-2 infection or disease or the ability to transmit infection to others.

Efficacy: Preliminary efficacy data were limited to the evaluable efficacy population from Cohort 1 (individuals who did not have evidence of SARS-CoV-2 infection prior to dose 2; 1,305 randomized to receive the vaccine; 663 randomized to receive placebo). As of October 8, 2021 (data cut-off date for analysis), a total of 19 confirmed, symptomatic cases of COVID-19 were identified at least 7 days after dose 2 of the Pfizer-BioNTech COVID-19 vaccine or placebo in study participants 5-11 years of age. The estimated efficacy of the vaccine against symptomatic COVID-19 from 7 days after dose 2 was 90.7% (95% CI: 67.7 to 98.3%; 3 cases identified in the vaccine group and 16 cases in the placebo group). An analysis of efficacy by various subgroups (sex, race, and ethnicity, presence of comorbidities, and country of recruitment) resulted in point estimates of vaccine efficacy (all above 85%) that were similar to the overall estimate. However, many of the subgroup efficacy estimates were based on a small number of cases, resulting in large confidence intervals around these point estimates.

The majority of confirmed cases in study participants were identified in August and September 2021, at a time when the Delta variant was the predominant circulating strain in the US and globally. However, no sequence analysis was reported on case isolates to determine whether they were caused by the Delta variant or another variant.

None of the identified cases met the pre-defined criteria for a severe case of COVID-19, therefore the data did not include estimates of vaccine efficacy against severe outcomes such as hospitalization, MIS-C or deathFootnote 31.

Myocarditis and/or pericarditis and MIS-C/A following mRNA COVID-19 vaccination

Cases of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the lining around the heart) have been reported following vaccination with mRNA COVID-19 vaccines in Canada and internationally among individuals aged 12 years and older who received the 30 mcg formulation of the Pfizer-BioNTech COVID-19 vaccine or 100 mcg formulation of the Moderna COVID-19 vaccine; however, the risk is considered rare. Symptoms of myocarditis/pericarditis can include shortness of breath, chest pain, or the feeling of a rapid or abnormal heart rhythm. Symptoms can be accompanied by abnormal test results (e.g., electrocardiogram, serum troponins, echocardiogram)Footnote 32. Available data indicate that most individuals affected have responded well to conservative therapy and have recovered quicklyFootnote 33.

Cases of myocarditis/pericarditis following COVID-19 mRNA vaccination occur most commonly in adolescents and young adults (12 to 30 years of age), more often after the second dose, more often in males than females, more often after Moderna than Pfizer-BioNTech, and usually within a week of vaccination. Emerging Canadian safety surveillance data suggest an extended interval between the first and second dose may reduce the risk of myocarditis/pericarditis associated with the second dose of an mRNA COVID-19 vaccine (note this data is currently under preparation for publication). Data from the US suggest the risk of myocarditis/pericarditis following mRNA COVID-19 vaccination may be higher in older adolescents aged 16-17 years compared to younger adolescents aged 12-15 yearsFootnote 33.

Myocarditis following mRNA COVID-19 vaccination tends to have a similar epidemiologic profile to classic myocarditis (unrelated to COVID-19), as it occurs more commonly in adolescents and young adult males. Classic myocarditis is less common in younger children 5-11 years of age. It is unknown whether myocarditis/pericarditis will occur after the lower doses of mRNA present within pediatric COVID-19 vaccines for children 5-11 years of ageFootnote 33.

Very rare cases of MIS-C/A (multisystem inflammatory syndrome; in children and in adults, respectively) have been reported following vaccination with COVID-19 mRNA vaccines in Canada and internationally among individuals aged 12 years and older. However, on October 29, 2021, the European Medicines Agency (EMA) Pharmacovigilance Risk Assessment Committee (EMA-PRAC) issued a statement that there is currently insufficient evidence on a possible link between mRNA COVID-19 vaccines and very rare cases of MIS-C/AFootnote 34.

Adult or adolescent and pediatric formulations of the Pfizer-BioNTech vaccine

Table 1. Adult or adolescent and pediatric formulations of the Pfizer-BioNTech vaccine
Product specification Adult or adolescent formulation Pediatric formulationTable 1 Footnote a
Age 12 years of age and over 5-11 years
Vial Cap Color Purple Orange
Diluent (Only use 0.9% Sodium Chloride Injection, USP as the diluent) 1.8 mL 1.3 mL
Dose 0.3 mL (30 micrograms) 0.2 mL (10 micrograms)
Doses per vial 6 10
Potential allergens Polyethylene glycol (PEG) Polyethylene glycol (PEG) Tromethamine (Tris, Trometamol)Table 1 Footnote b
Post-dilution time
Can be at room temperature
6 hours 12 hours
Ancillary supplies Low dead volume needle/syringe Low dead volume needle/syringe
StorageTable 1 Footnote cTable 1 Footnote e
  • Ultra-frozen up to 6 months from the date of manufacture printed on the vial and cartonsTable 1 Footnote a
  • Do no store frozen
  • RefrigeratedTable 1 Footnote d for up to 10 weeks
  • Room temperatureTable 1 Footnote d for:
    • up to 12 hours prior to dilution;
    • up to 12 hours after dilution (i.e., post first puncture)
TransportTable 1 Footnote c
  • Ultra-frozen full cartons containing vials
  • RefrigeratedTable 1 Footnote d full cartons or individual undiluted vials

For complete prescribing information for the pediatric and adult formulations of the Pfizer-BioNTech vaccine, consult the product leaflet or information contained within Health Canada's authorized product monographs available through the Drug Product Database.


Refer to Table 2 for a summary of immunization schedules for authorized COVID-19 vaccines for children 5-11 years of age.

Table 2. Immunization schedule for primary series, by COVID-19 vaccine
Vaccine Product Dose Immunization Schedule Minimum Interval Authorized Interval NACI - Recommended IntervalTable 2 Footnote 1
Pfizer-BioNTech (Comirnaty; 10 mcg) 0.2mL 2-dose schedule 19 days 21 days At least 8 weeks

Evidence to inform an optimum dosing interval for the primary series of an mRNA COVID-19 vaccine

Shorter intervals between doses of COVID-19 mRNA vaccines result in lower antibody titres, which may wane to below protective levels more quickly over time. Currently, there is no direct evidence to establish an optimal interval between doses in pediatric populations. However, evidence on COVID-19 mRNA vaccines in adult populations indicates that a longer dose interval such as 8 weeks, compared with the authorized 21-day interval, improves the immune response and is associated with greater vaccine effectiveness that may last longer, which is consistent with general principles of vaccinologyFootnote 37Footnote 38Footnote 39. In addition, emerging Canadian safety surveillance data suggest an extended interval between the first and second dose may reduce the risk of myocarditis/pericarditis following the second dose of an mRNA COVID-19 vaccine (note this data is currently under preparation for publication).

Ethics considerations on the use of the Pfizer-BioNTech COVID-19 vaccine in children 5-11 years of age

The guiding consideration for COVID-19 pediatric vaccine recommendations should be whether vaccination is in children's best interests. Decisions regarding pediatric COVID-19 vaccination programs should not only evaluate the direct and indirect benefits and risks of vaccination in this age group, but also consider principles such as the precautionary principle, equity, trust, and proportionality. There are multiple and intersecting uncertainties at play, including those related to the impact of COVID-19 on children's health; the long-term effectiveness of vaccination in this age group; potential safety concerns (e.g., uncertainty around the risk of myocarditis and pericarditis); and the future progression of the pandemic, including the emergence of variants of concern. While it is not justified to vaccinate children only to benefit others, the indirect, population-level benefits of vaccination can also benefit children.

The overall safety and effectiveness data are limited for children. While it is justifiable to make recommendations based on available data for children 5-11 years of age, including following the dosing intervals associated with the clinical trial data, the precautionary principle also justifies taking action under conditions of scientific uncertainty to mitigate vaccine-related risks, including through active post-market surveillance. This includes using data available from other age groups and applying vaccination principles.

Generally, a vaccination program is justified if its anticipated benefits outweigh its potential risks. Children aged 5-11 years are unlikely to be deemed capable of consenting to vaccination, and decisions related to their vaccination will likely be made by parents or guardians. Given the short-term uncertainties surrounding pediatric vaccination at this time, children and their parents or guardians should be supported and respected in their decisions regarding COVID-19 vaccinations for the child, whatever decisions they make, and should not be stigmatised for accepting, or not accepting, the vaccination offer.


NACI recommends that a complete series with the Pfizer-BioNTech COVID-19 vaccine (10 mcg) may be offered to children 5-11 years of age who do not have contraindications to the vaccine, with a dosing interval of at least 8 weeks between first and second dose. (Discretionary NACI Recommendation)

Additional considerations, summary of evidence, and rationale

Research priorities


This statement was prepared by: N Forbes, M Salvadori, J Zafack, J Montroy, R Stirling, R Krishnan, B Warshawsky, E Wong, E Abrams, S Ismail, K Young, M Tunis, R Harrison and S Deeks on behalf of NACI.

NACI gratefully acknowledges the contribution of: K Farrah, K Ramotar, N St-Pierre, L Coward, C Jensen, A Nam, R Ximenes, MW Yeung, A Tuite, SH Lim, and the NACI Secretariat.

NACI Members: S Deeks (Chair), R Harrison (Vice-Chair), J Bettinger, N Brousseau, P De Wals, E Dubé, V Dubey, K Hildebrand, K Klein, J Papenburg, A Pham-Huy, C Rotstein, B Sander, S Smith, and S Wilson.

Liaison representatives: L Bill (Canadian Indigenous Nurses Association), LM Bucci (Canadian Public Health Association), E Castillo (Society of Obstetricians and Gynaecologists of Canada), A Cohn (Centers for Disease Control and Prevention, US), L Dupuis (Canadian Nurses Association), D Fell (Canadian Association for Immunization Research and Evaluation), S Funnell (Indigenous Physicians Association of Canada), J Hu / N Ivers (College of Family Physicians of Canada), M Lavoie (Council of Chief Medical Officers of Health), D Moore (Canadian Paediatric Society), M Naus (Canadian Immunization Committee), and A Ung (Canadian Pharmacists Association).

Ex-officio representatives: V Beswick-Escanlar (National Defence and the Canadian Armed Forces), E Henry (Centre for Immunization and Respiratory Infectious Diseases [CIRID], PHAC), M Lacroix (Public Health Ethics Consultative Group, PHAC), C Lourenco (Biologic and Radiopharmaceutical Drugs Directorate, Health Canada), D MacDonald (Vaccine Safety, PHAC), S Ogunnaike-Cooke (CIRID, PHAC), G Poliquin (National Microbiology Laboratory, PHAC), K Robinson (Marketed Health Products Directorate, HC), and T Wong (First Nations and Inuit Health Branch, Indigenous Services Canada).

NACI High Consequence Infectious Disease Working Group

Members: R Harrison (Chair), N Brousseau, Y-G Bui, S Deeks, K Dooling, K Hildebrand, M Miller, M Murti, J Papenburg, D Smith, and S Vaughan.

PHAC Participants: N Abraham, L Coward, N Forbes, C Jensen, R Krishnan, S Ismail, J Montroy, A Nam, M Salvadori, A Sinilaite, R Stirling, E Tice, A Tuite, B Warshawsky, R Ximenes, MW Yeung, and J Zafack.


Abbreviation Term

Adverse event
Adverse event following immunization
Alberta Research Center for Health Evidence
Confidence Interval
Canadian Immunization Committee
Coronavirus disease 2019
Geometric mean ratio
Geometric mean titre
Intensive Care Unit
Multisystem Inflammatory Syndrome in Children
Messenger Ribonucleic Acid
National Advisory Committee on Immunization
SARS-CoV-2 50% neutralizing titres
Public Health Agency of Canada
Public Health Ethics Consultative Group
Polymerase Chain Reaction
Serious adverse event
Severe Acute Respiratory Syndrome Coronavirus 2
United States
Vaccine efficacy

Appendix A: Frequency of solicited adverse events following immunization for COVID-19 in clinical trials

Table 1. Frequency of solicited local AEs in 5 to 11 year olds for the Pfizer-BioNTech COVID-19 vaccine (ComirnatyTM)Table 1 Footnote aTable 1 Footnote b
AEFI Vaccine Placebo control

Dose 1


Dose 2


Dose 1


Dose 2


Pain at injection site 74.1% 71.0% 31.3% 29.5%
Redness/erythema 14.7% 18.5% 5.7% 5.4%
Swelling 10.5% 15.3% 2.7% 2.7%


  • AEFI: adverse event following immunization vaccine
  • NS: not solicited
Table 2. Frequency of solicited systemic AEs in 5 to 11 year olds for the Pfizer-BioNTech COVID-19 vaccine (ComirnatyTM) Table 2 Footnote aTable 2 Footnote c
AEFI Vaccine Placebo control

Dose 1


Dose 2


Dose 1


Dose 2


Fatigue 33.6% 39.4% 31.3% 24.3%
Headache 22.4% 28.0% 24.1% 18.6%
Muscle pain 9.1% 11.7% 6.8% 7.4%
Chills 4.6% 9.8% 4.7% 4.3%
Joint pain 3.3% 5.2% 5.5% 3.6%
FeverTable 2 Footnote b 2.5% 6.5% 1.3% 1.2%
Diarrhea 5.9% 5.3% 4.1% 4.7%
Vomiting 2.2% 1.9% 1.5% 0.8%


  • AEFI: adverse event following immunization vaccine
  • NS: not solicited

Page details

Date modified: